IK01400: non-opioid preclinical drug candidate for pain treatment
|
|
- Candace Richard
- 5 years ago
- Views:
Transcription
1 IK01400: non-opioid preclinical drug candidate for pain treatment Introduction Bio-Link presents a valuable licensing opportunity for the development of novel nonopioid drug candidates to manage acute and chronic pain. InterK Peptide Therapeutics Ltd (InterK) is a cancer drug discovery company focused on selective activators of Lck kinase, a member of the Src family of kinases which are intracellular signaling molecules that regulate a diverse range of cell functions. The InterK drug discovery program has led to the fortuitous discovery of peptide candidates with in vivo efficacy in reducing pain after oral, intraperitoneal and intrathecal administration. Lead pain candidates IK01400 and its D-isomer IKD01400 are both potent in vitro inhibitors of PKG-1α, with IC50 values under 10nM. PKG-1α mediates pain by increasing the release of neurotransmitters in dorsal root ganglia upon pain receptor (nociceptor) activation 1. As a result, the IK01400 leads block the sensation of pain after nerve injury and peripheral nerve stimulation, offering a complementary mechanism of action for the treatment of post-operative, neuropathic and inflammatory pain. InterK has generated extensive preclinical data demonstrating in vivo efficacy and non-toxicity of the lead candidates in two important pain models. Oral administration of IKD01400 in an inflammatory pain model, and intrathecal administration of IK01400 in a neuropathic pain model, both kill pain with equal or better efficacy than morphine. InterK s lead compounds have potential to be developed as an alternative to opioid drugs, reducing the associated risk of abuse, addiction, morbidity and mortality. As pain management lies outside InterK s core focus, the company seeks to out-license the IK01400 pain program. Companies interested to diversify or enrich their drug development pipeline with a promising, non-opioid drug candidate for pain management, are invited to evaluate InterK s program and IK01400 candidates as a potential in-licensing opportunity. Pain background and market opportunity Pain is categorized in two classes, acute and chronic, based on its duration. Nociception associated with acute pain arises from tissue damage, which can occur after injury or surgery. Chronic pain can be classified as inflammatory or neuropathic. Inflammatory pain is associated with the inflammation process that ensues after tissue damage, while neuropathic pain can emerge from damage or dysfunction of the peripheral or central nervous system. Chronic pain is often the result of a combination of inflammatory and neuropathic pain. The following metrics indicate a significant unmet medical need and a large market opportunity for non-opioid drugs that can effectively treat patients suffering pain: Opioid crisis in the US Opioids are the current mainstay for post-operative pain, despite their side effects including respiratory depression, insomnia, memory deficits, nausea, and addiction. Opioid abuse is of particular concern in the US, where 215 million opioid prescriptions were dispensed in 2016 and where 2.5 million adults are addicted to opioids, resulting in over 20,000 deaths annually. 1
2 The global pain management therapeutics market is estimated to be worth over $83 billion by 2024, with a CAGR of 3.5%. About one third of the market is comprised of opioid drugs. Globally 230 million surgeries are performed annually, in which up to 75% of the patients suffer from moderate to extreme acute post-operative pain 2 and more than 50% report inadequate pain relief. The post-operative pain market is estimated to be $6.2 billion in the US alone. Chronic pain reportedly arises in 10% to 50% of the patients undergoing surgery 3. Over 100 million adults in the USA suffer from chronic pain and the annual economic losses due to chronic pain is estimated to be around $600 million, a number that is steadily increasing with an ageing population 4. An estimated 7% to 10% of the general population experience chronic pain with neuropathic characteristics. 75% of patients treated for neuropathic pain report no significant pain relief. For those that do benefit the pain is only partly reduced (by about 50%) 5. The healthcare and disability-related costs due to neuropathic pain is substantial, estimated at almost $40 billion annually in the US alone 6. The anticonvulsant Pregabalin (LYRICA, Pfizer) is one of the leading products in the neuropathic pain market yielding a global revenue of $5 billion in 2016, despite having various CNS side-effects. In several countries, generic competitors are eroding LYRICA s blockbuster status. Preclinical in vivo efficacy inflammatory pain model i. Oral administration The analgesic efficacy of IKD01400 was tested against the current standard of care (morphine) in an inflammatory pain model where the left hindpaws of mice are injected with Complete Freund s Adjuvant (CFA) and consequently develop inflammation. Differences in weight-bearing across treated and untreated paws were assessed using the Linton Incapacitance tester. IKD01400 and morphine were given orally at approximately 200 and 10 mg/kg, respectively, Figure 1. Vehicle (water, n=6) Morphine (240 ug, n=6) IKD01400 (4800 ug, n=6) Figure 1. Incapacitance (analgesic effect) of IKD01400 and morphine in an inflammatory pain model. Weight-bearing was assessed after CFA injection for left and right paws at the times indicated. Error bars are standard errors. 2
3 L:R weight distribution Our in vivo data in inflammatory pain models demonstrate a similar incapacitance effect (feeling of pain) between IKD01400 and morphine after oral administration. To exclude the possibility that measured pain relief was due to paw paralysis, grip-strength was determined for all mice at various time points, Figure 2. There was no significant difference between vehicle control and IKD As the mice were alert at all time points, the increased grip strength seen for morphine-treated mice was due to the side effects of morphine, i.e. hyperactivity. Vehicle (water, n=6) Morphine (240 ug, n=6) IKD01400 (4800 ug, n=6) ii. Figure 2. Assessment of grip strength in CFA animal models after oral administration of IKD01400, morphine or vehicle control. The dotted line represents the average baseline scores for pain-free animals before CFA injection. Error bars are standard errors. Intraperitoneal administration Additional in vivo data in CFA animal models suggest that IK01400 has a more potent analgesic effect than morphine after intraperitoneal (i.p.) administration. To determine a potential dose/response effect for IK01400, data were pooled for experiments performed on three different dates. The data suggest that higher doses of intraperitoneally administered IK01400 are more effective than lower doses. Furthermore, morphine appears more effective during the first 30 minutes after injection but less effective than the higher dose of IK01400 during the second hour of testing, Incapacitance Figure IK01400 (200ug, n = 8) IK01400 (100ug, n = 4) Morphine (240 ug, n = 9) Time Time (mins) Figure 3. Incapacitance (analgesic effect) of intraperitoneally administered IK01400 and morphine in an inflammatory pain model. Data pooled from 3 separate experiments. 3
4 von Frey Threshold The in vivo data from the inflammatory pain model (Figures 1-3) indicate that IKD01400 and IK01400 have comparable in vivo efficacy to morphine. IKD01400 was given orally at a relatively high dose to mitigate against the risk of digestive degradation; lower doses were not investigated. However, after i.p. administration, IK01400 demonstrated 16 times higher potency on a molar basis compared to morphine. Precisely, a 100ug (45 nmol) dose of IK01400 had the same analgesic effect as a 240ug (746 nmol) dose of morphine, Table 1. Table 1: Dosage and molarity of IKD01400 and IK01400administration in CFA mouse model Route of administration MW Dose Vol. Av. weight g/mol mg mg/kg mm nmol ul kg Molar ratio Morphine:IK Morphine Oral/i.p n/a IK01400 i.p IK01400 i.p IKD01400 Oral Preclinical in vivo efficacy neuropathic pain model IK01400 was also tested in a model of neuropathic pain, in which rats are surgically injured through partial nerve ligation at the sciatic nerve in the left hindpaw. Mechanical allodynia (pain due to a stimulus that does not usually provoke pain) was assessed using the von Frey nociceptive test, a well-established, objective and quantitative assay where von Frey hairs are applied to a rat s paw causing a paw withdrawal response. In control animals, the paw withdrawal response is almost instantaneous; in a rat under analgesia, withdrawal is only observed as the von Frey threshold (force applied) increases, Figure Time (mins) Figure 4. The analgesic effect of 5.4 μg IK01400 (2.4 nmol) and 3.0 μg morphine (10 nmol) injected intrathecally in a neuropathic pain model. The higher the von Frey threshold, the greater the stimulus required for the rat to respond, indicating a greater analgesic effect. Both IK01400 and morphine demonstrate an analgesia effect at the first 15 minutes; at 90 minutes the effect is almost identical and remains stable up to 3 hours. In the neuropathic pain model, IK01400 had analgesic efficacy comparable to that of morphine, despite being administered intrathecally at a molar dose 4 times lower (2.4 nmol IK01400 vs 10 nmol morphine). In addition, the analgesic effect of IK01400 lasted as long as that of morphine (3 hours), despite its shorter half-life compared to morphine (<0.5h vs <2h for morphine). 4
5 Overall, the preclinical in vivo data demonstrate a time course of pain relief for the IK01400 candidates that could potentially support their use alone, or in combination with morphine, for effective and sustained analgesia in inflammatory and neuropathic pain. Nonclinical biodistribution and toxicity studies Toxicity studies demonstrate that intravenous administration of IK01400 was well tolerated in rats up to 20 mg/kg, though some temporary adverse reactions were noted at doses of 15 and 20 mg/kg. IKD01400 effectively killed pain and had no observed toxicity after oral administration of a relatively high dose of about 200 mg/kg in the mouse. Neglecting the potential efficacy of lower doses (yet to be investigated), an equivalent oral dose in an average 70 kg human would be about 15 grams, which may approach the feasibility range for daily dosage. As a further indication of non-toxicity, the IK01400 leads had no effect on body weight of rats, or any haematology or pathology parameters at all doses tested. Biodistribution data in mice indicate that oral and intravenous administration of the IK01400 peptides accumulate in all major organs including the liver, kidney and gut, with peptide clearance occurring through several mechanisms including the renal and biliary systems. An example of biodistribution data is shown in Figure 5, indicating renal clearance as major disposal route at 4 hours post administration. Figure 5. In vivo PET-CT images of IK14820 distribution 4hrs post administration. Accumulation of the peptide in the bladder suggests renal clearance of the peptide. Following oral administration of 1mg of Cu 64 -labelled IK01400 and IKD01400 in mice, PET-CT scans show mean percentage injected dose per gram (%ID/g) in the blood around 0.05% for both peptides. IK01400 s %ID/g value remains almost unchanged between the 4 th and 20 th hour post administration, while the D-isomer, IKD01400, presents a non-significant increase of %ID/g value at the 20 th hour after administration (Figure 6A). At 20 hours post oral administration of only 1mg, accumulation of IK01400 and IKD01400 is detectable in tissues frequently associated with pain, including bone, skin, and muscle (Figure 6B). The observed oral efficacy despite relatively low retention in pain-associated tissues, suggests significant potency of the IK compounds that may enable efficacious transdermal delivery for skin surface, inflammatory and joint pain. 5
6 % ID/g % ID/g O r g a n s Percentage ID/g A PEPTIDE RETENTION Blood Samples IN BLOOD B IK IKD01400 D Hours 20 Hours % ID /g Percentage ID/g B lo o d s a m p le s 1.5 B r a in IK PEPTIDE RETENTION Organs IN ORGANS AT 20 HOURS % ID /g IK L iv e r B lo o d 4 H S p le e n K id n e y s T is s u e H e a rt B lo o d 2 0 H L u n g s T h y m u s IK IKD IK IKD01400 T ib ia S k in M u s c le IK IK IK IK D IK IK D T is s u e Figure 6. Retention of Cu 64 -labelled IK01400 and IKD01400 administered orally in mice. A) In blood at 4 and 20 hours post administration; B) In brain, liver, spleen, kidneys, heart, lung, thymus, tibia, skin and muscle at 20 hours post administration. Clinical development strategy Having demonstrated potent in vivo analgesic effects of the IK01400 compounds via various routes of administration, InterK s pain program is well positioned for lead optimization prior to commencement of repeat-dose toxicity studies. The overall clinical development strategy aims to develop the IK01400 lead candidate as a novel, non-opioid analgesic for post-operative, neuropathic and inflammatory pain. After completion of lead optimization, formal preclinical ADME and toxicology studies must be conducted to enable filing of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). A positive evaluation by the FDA will allow initiation of clinical trials in humans. Based on pain drug development programs conducted by other companies, a Phase 1 clinical trial typically requires between 30 to 80 subjects. For a Phase 2 proof-of-concept study, between 60 to 200 patients will be required. Phase 3 trials in pain usually involve more than 1000 patients and require significant financial resources. Demonstration of Phase 2 proof of concept in a human clinical study would add significant value and likely substantiate a commercial partnership with a major pharmaceutical company for further clinical and commercial development. Intellectual property InterK owns all intellectual property associated with its drug development programs, including a number of patent families covering compositions of matter and methods of use for therapeutic agents. InterK s pain management program offers maximum patent life in major markets worldwide through provisional patent application(s) covering method of use for the IK01400 lead peptides. 6
7 InterK Peptide Therapeutics InterK is based in Sydney, Australia, and is a privately owned, virtual biotechnology company developing immune-boosting peptide drug candidates for a range of therapeutic indications, including cancer and chronic infections. The Company s focus is on the discovery of selective activators of Lck kinase, a member of the Src family of kinases which are non-receptor membrane-bound signaling molecules that regulate a diverse range of cell functions. Lck modulates immune function, specifically T-cell activation. In support of this work, InterK was awarded two federally-funded Australian Research Council (ARC) Linkage Grants with the Lowy Cancer Research Centre and the Australian Institute for Bioengineering and Nanotechnology. While screening its peptides for modulation of kinase activity, InterK discovered a set of peptides with analgesic properties, including IKD As therapeutic applications for pain lies outside InterK s corporate development plan, InterK is seeking external development partnerships for the IKD01400 peptides. Commercial Opportunity Bio-Link Australia is a specialist business development consultancy that works with Australian and international biotech companies and biomedical research institutions to facilitate commercialisation of innovative biotechnologies. Bio-Link has been engaged by InterK to secure a licensing and commercial development partner for the remaining preclinical and clinical development of the selected lead IK01400 candidate. Companies are invited to express their interest by contacting Christopher Boyer at Bio-Link. Christopher Boyer, Executive Director 108 South Parade, Blackburn VIC 3130 Australia Tel c.boyer@bio-link.com References 1. Sung et al. (2017) Pain. 158(5): Katz et al. (2017) Curr Med Res Opin. 33: Gan et al. (2014) Curr Med Res Opin. 30: Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington: The National Academies Press (2011) 5. Nightingale (2012) Nat Rev Drug Discov. 11(2): Gilron (2012) Neuropathic Pain. Mechanisms, Diagnosis and Treatment. Ed. Simpson, McArthur & Dworkin 7
NEUROFIX S MISSION & VISION
NEUROFIX S MISSION & VISION MISSION Neurofix aims to discover and develop innovative therapies for the treatment of neurological disorders. Our main focus now is Spinal Cord Injury. VISION Spinal Cord
More informationThe Challenge of Treating Pain
FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and
More informationNOVEL MEDICATION FOR NEUROPATHIC PAIN
NOVEL MEDICATION FOR NEUROPATHIC PAIN NRD.E1 a treatment for diabetic related neuropathic pain Novaremed s Dr Eli Kaplan shares research on NRD.E1 and explains how it can help to treat diabetic related
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationDynamin Drug Discovery Program for Epilepsy
Dynamin Drug Discovery Program for Epilepsy Introduction Bio-Link presents a unique drug discovery program focused on modulation of the GTPase activity of dynamin for the treatment of epilepsy and other
More informationPN6047; a potent and. selective delta opioid receptor agonist, effective against chronic pain
PN6047; a potent and selective delta opioid receptor agonist, effective against chronic pain Therapeutic target Chronic pain varies from mild discomfort to the worst pain imaginable. In the UK, the total
More informationYour partner for Medical Research and Development
Your partner for Medical Research and Development Overview Integrated place for clinical research SERVICES AND RESOURCES DNA Sequencing Proteomics Imaging Histology Flow Cytometry Sample Processing Cryogenics
More informationPotential for delta opioid receptor agonists as analgesics in chronic pain therapy
Potential for delta opioid receptor agonists as analgesics in chronic pain therapy David Kendall & Bengt von Mentzer; PharmNovo AB/UK Alex Conibear & Eamonn Kelly, University of Bristol Junaid Asghar,
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationTitan Pharmaceuticals Overview
Corporate Presentation July 2014 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationCathepsin S Inhibitors for the Treatment of Inflammatory Bowel Disease. Therapeutic Area Partnerships Presentation.
Inhibitors for the Treatment of Inflammatory Bowel Disease Therapeutic Area Partnerships Presentation November 29, 2012 Cathepsin Cysteine Proteinases Fibrosis Cathepsin O Cathepsin B Cathepsin C Cathepsin
More informationStrengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018
Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress REDUCING THE PAIN FACTOR AN UPDATE ON PERI-OPERATIVE ANALGESIA Sandra Forysth, BVSc DipACVA Institute of Veterinary,
More informationPRESENTATION TO INVESTORS. I attach a PowerPoint presentation as presented by Biotron Limited's CEO, Dr Michelle Miller, to investors today.
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 11 November 2010 The Manager Companies ASX Limited
More informationSprays for pain management as an alternative to injection and other routes of administration
Prescription Division Sprays for pain management as an alternative to injection and other routes of administration A scientific roundtable hosted by Aptar Pharma Prescription Division Delivering solutions,
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationWhat do we want for pain medications?
New Trends in Pain Pharmacotherapy Dr. Chi Wai Cheung MBBS(HK), FHKCA, FHKAM(Anaesthesiology), Dip Pain Mgt(HKCA) Clinical Assistant Professor Department of Anaesthesiology The University of Hong Kong
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationNEWSLETTER June Summer greetings from Follicum
NEWSLETTER June 2018 Follicum hopes that this newsletter reaches as many of the company's owners and stakeholders as possible. If you wish to follow our continued development, please register your e-mail
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationTofacitinib ( Xeljanz) Marshall Porter & Lauren Ysais
Tofacitinib ( Xeljanz) Marshall Porter & Lauren Ysais Learning Objectives to Take with You A small molecule Janus Kinase (JAK) Inhibitor treatment for moderate to severe rheumatoid arthritis (RA) reduces
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationMedia Kit. September 2017
Media Kit September 2017 About Pear Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company s approach is to integrate clinically-validated software applications with
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationCharlie Taylor, PhD CpTaylor Consulting Chelsea, MI, USA
Contribution of Calcium Channel α 2 δ Binding Sites to the Pharmacology of Gabapentin and Pregabalin Charlie Taylor, PhD CpTaylor Consulting Chelsea, MI, USA Disclosure Information Charlie Taylor, PhD
More informationCorporate Presentation
Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities
More informationAnalgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I. Mr.D.Raju,M.pharm, Lecturer
Analgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I Mr.D.Raju,M.pharm, Lecturer Mechanisms of Pain and Nociception Nociception is the mechanism whereby noxious peripheral stimuli are transmitted to
More informationALMIRALL AND IRONWOOD ANNOUNCE POSITIVE RESULTS FROM A PHASE 3 TRIAL WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Almirall Contact: Susan Brady Ketchum Pleon Corporate Communications Amanda Sefton 617.621.8304 +44 (0) 207.611.3653 sbrady@ironwoodpharma.com amanda.sefton@ketchumpleon.com
More informationGuidelines on the Safe Practice of Acute Pain Management
Page 1 of 7 Guidelines on the Safe Practice of Acute Pain Version Effective Date 1 1 MAY 1994 (Reviewed Feb 2002) 2 1 DEC 2014 Document No. HKCA P11 v2 Prepared by College Guidelines Committee Endorsed
More informationOncology Program. Chlorotoxin Technology Platform. Corporate Partnering Opportunities
TransMolecular, Inc. A Neuroscience Biotechnology Company Oncology Program Chlorotoxin Technology Platform Corporate Partnering Opportunities Background TransMolecular, Inc. (TMI) is a neuroscience biotechnology
More informationSosei Group Corporation
Sosei Group Corporation Shinichi Tamura President and CEO www.sosei.com Sosei History - Background Incorporated in Japan in 1990 and traded initially as a technology transfer company In 1999 switched to
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationTREATING NEUROINFLAMMATION, TREATING DISEASE
TREATING NEUROINFLAMMATION, TREATING DISEASE NeuroTherapia Developing novel biopharmaceuticals for the treatment of neuroinflammatory disorders NOVEL STRATEGY FOR REDUCING NEUROINFLAMMATION SIGNIFICANT
More informationAnti-epilepsy Drug VIMPAT for I.V. infusion 200mg Launched in Japan
Press Release March 25, 2019 UCB Japan Co., Ltd. Daiichi Sankyo Company, Limited Anti-epilepsy Drug VIMPAT for I.V. infusion 200mg Launched in Japan UCB Japan Co., Ltd. (headquarters: Shinjuku-ku, Tokyo;
More informationBrian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD
Brian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD 1630 Main Street Suite 215 Chester, MD 410-571-9000 www.4-no-pain.com
More informationSubject: Pain Management (Page 1 of 7)
Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all
More informationmicrorna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease
microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease January 2018 Safe Harbor Statement Statements contained in this presentation regarding matters that are not
More informationi-bodies a new class of protein therapeutics to treat fibrosis
i-bodies a new class of protein therapeutics to treat fibrosis BIOSHARES JULY 2017 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is subject
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationAXIM Biotechnologies Reports Year End 2017 Results
March 19, 2018 AXIM Biotechnologies Reports Year End 2017 Results NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research
More informationNIH HEAL Initiative: Program Update and Funding Opportunities for Pain Research Available through NIH
NIH HEAL Initiative: Program Update and Funding Opportunities for Pain Research Available through NIH AAMC Webinar November 8, 2018 Walter J. Koroshetz, MD Director, National Institute of Neurological
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve 50 mg/ml solution for injection for dogs (AT, BE, BG, CY, CZ, DE, EL, ES, HR, HU, IE, IT, LU, NL, PT, RO,
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:
More informationDeveloping Xanamem for Alzheimer s Dementia
Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015 Forward Statements This presentation has been prepared by Actinogen Limited. ( Actinogen
More informationFirst-in-Class Dimer Therapeutics to Bring Relief to Patients with Gastrointestinal Disorders
First-in-Class Dimer Therapeutics to Bring Relief to Patients with Gastrointestinal Disorders BIO CEO & Investor Conference February 2018 Forward-Looking Statement This presentation contains forward-looking
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationThe Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010
The Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010 EXECUTIVE SUMMARY It is well documented in multiple
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationCorporate Presentation Asia Investment Series March 2018
Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United
More informationMerrill Lynch Healthcare Conference New York
Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline
More informationREFERENCE CODE GDHC407DFR PUBLICAT ION DATE APRIL 2014 QUTENZA (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC407DFR PUBLICAT ION DATE APRIL 2014 QUTENZA (NEUROPATHIC PAIN) - Executive Summary Table below provides a summary of the key metrics for Qutenza in the 7MM neuropathic pain markets during
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationMitigating the Opioid Crisis in Alabama (MOCA)
Mitigating the Opioid Crisis in Alabama (MOCA) April 11, 2018 Tino Unlap PHD, CRA Professor Director, UAB Biotechnology Program Clinical and Diagnostic Sciences Dept. Director, Innovative Teaching The
More informationRespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit
RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit December 11 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston,
More informationANNEX III LABELLING AND PACKAGE LEAFLET
ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Outer carton Multi-pack 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationTackling Osteoarthritis: Matriptase Inhibitor as a Disease Modifying Therapy Kevin Buchan
Tackling Osteoarthritis: Matriptase Inhibitor as a Disease Modifying Therapy Kevin Buchan Business Development Manager, LifeArc Tackling Osteoarthritis Osteoarthritis (OA) is the most common joint disorder
More informationThe Impact of Opioid Use and Abuse on Medical Community, Businesses, Social Organizations and Individiuals and Their Families
The Impact of Opioid Use and Abuse on Medical Community, Businesses, Social Organizations and Individiuals and Their Families THE MAGNITUDE OF THE OPIOID EPIDEMIC THE COSTS TO LOCAL, STATE AND NATIONAL
More information2/20/2019. Source: Source:
The misuse of and addiction to opioids including prescription pain relievers, heroin, and synthetic opioids such as fentanyl is a serious national crisis that affects public health as well as social and
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationPAIN TERMINOLOGY TABLE
PAIN TERMINOLOGY TABLE TERM DEFINITION HOW TO USE CLINICALLY Acute Pain Pain that is usually temporary and results from something specific, such as a surgery, an injury, or an infection Addiction A chronic
More informationSeptember 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic
National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC 20036 RE: Prescription Opioid Epidemic On behalf of America s Health Insurance Plans (AHIP), thank you for your leadership
More informationResearch Priorities of NIDA s Medications Development Program
Research Priorities of NIDA s Medications Development Program Iván D. Montoya, M.D., M.P.H. Deputy Director, Division of Therapeutics and Medical Consequences NIDA No Disclosures NIDA Medications Development
More informationGG&C Chronic Non Malignant Pain Opioid Prescribing Guideline
GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline Background Persistent pain is common, affecting around five million people in the UK. For many sufferers, pain can be frustrating and disabling,
More informationChronic Pain in Women and its Relationship to Opioid Addiction
Chronic Pain in Women and its Relationship to Opioid Addiction Advancing Addiction Science Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse OPIOIDS are Powerful Analgesics
More informationAdvancing Addiction Science to Address the Opioid Crisis
Advancing Addiction Science to Address the Opioid Crisis National Institute on Drug Abuse Bringing the full power of science to bear on drug abuse and addiction Nora D. Volkow, M.D. Director National Institute
More informationNovel Compounds for Anxiety, Epilepsy, and Neuropathic Pain
ovel Compounds for Anxiety, Epilepsy, and europathic Pain (OTT ID 1268) Inventors: James Cook, Ph.D. (Lead Inventor and PI) Department of Chemistry and Biochemistry UW-Milwaukee For further information
More informationREFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Fibromyalgia: Key Metrics in Seven Major Pharmaceutical Markets, 2013
More informationFounded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options
Founded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options Integrated platform technology for discovery of novel molecular targets and
More informationASX ANNOUNCEMENT CELLMID CEO TO PRESENT AT WHOLESALE INVESTOR CONFERENCE
ASX ANNOUNCEMENT CELLMID CEO TO PRESENT AT WHOLESALE INVESTOR CONFERENCE SYDNEY, Tuesday, 20 November 2012: Cellmid Limited (ASX: CDY) CEO, Maria Halasz, will present today at the Wholesale Investor Conference,
More informationMissouri Guidelines for the Use of Controlled Substances for the Treatment of Pain
Substances for the Treatment of Pain Effective January 2007, the Board of Healing Arts appointed a Task Force to review the current statutes, rules and guidelines regarding the treatment of pain. This
More informationShining a Light on MEDs Understanding morphine equivalent dose
Shining a Light on MEDs Understanding morphine equivalent dose In the workers compensation industry, 60.2 percent of claimants utilize opioid analgesics for the treatment of pain caused by a workplace
More informationREFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Neuropathic Pain (NP) in the US The US NP market was valued
More informationSARCOPHAGINE CHELATORS AND COPPER ISOTOPES FOR IMAGING AND THERAPY
SEEING IS BELIEVING SARCOPHAGINE CHELATORS AND COPPER ISOTOPES FOR IMAGING AND THERAPY Sydney Vital and STEaM Neuroendocrine Tumour Preceptorship May 2018 Amos Hedt Head of Clinical Development 1 CLARITY
More informationOragenics Shareholder Update
January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationTitan Pharmaceuticals: Highlights
Corporate Presentation January 2013 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
More informationChoose a category. You will be given the answer. You must give the correct question. Click to begin.
Instructions for using this template. Remember this is Jeopardy, so where I have written Answer this is the prompt the students will see, and where I have Question should be the student s response. To
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationIRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Forest Contact: Susan Brady Frank J. Murdolo Corporate Communications Vice President, Investor Relations 617.621.8304 212.224.6714 sbrady@ironwoodpharma.com frank.murdolo@frx.com
More informationChronic Pain: Decreasing Dependence on Opioids
University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2016 Chronic Pain: Decreasing Dependence on Opioids Derek Luzim Follow this and additional
More information20% A Holistic Approach Built on Evidence OF U.S. ADULTS EXPERIENCE MENTAL ILLNESS EACH YEAR
BEHAVIORAL HEALTH NEARLY 20% OF U.S. ADULTS EXPERIENCE MENTAL ILLNESS EACH YEAR Source: SAMHSA, 2018. Key substance use and mental health indicators in the United States: Results from the 2017 National
More informationPOST-OP MULTIMODAL PAIN MANAGEMENT. Maripat Welz-Bosna Reading Hospital Medical Center Department of Medicine Hospitalist Services/Pain Management
POST-OP MULTIMODAL PAIN MANAGEMENT Maripat Welz-Bosna Reading Hospital Medical Center Department of Medicine Hospitalist Services/Pain Management Objectives Understand the basic neurobiology of the pain
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis
More informationWhat EU research policy can do for conditions such as chronic pain?
The EU Framework Programme for Research and Innovation HORIZON 2020 What EU research policy can do for conditions such as chronic pain? K Berkouk, PhD Deputy Head of Unit, Non-communicable diseases and
More informationMerck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA
October 23, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Phone: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Phone: +81-3-6272-1001 Merck & Co, Inc. Announced Approval of JANUVIA
More informationAs part of the Opioid Analgesic REMS, all opioid analgesic companies must provide the following:
Introduction FDA s Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain (January 2018) Background In July 2012, FDA approved
More informationNMDA-Receptor Antagonists and Opioid Receptor Interactions as Related to Analgesia and Tolerance
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S7 Proceedings Supplement NDMA-Receptor Antagonists: Evolving Role in Analgesia NMDA-Receptor Antagonists and Opioid Receptor Interactions
More information